BioSpace News Archive

Infiniti Research, a leading market intelligence solutions provider, has recently announced the completion of its latest success story on market intelligence solution.

Scientists from the U.S. Department of Energy’s Argonne National Laboratory and the University of Chicago entangled photons across a 52-mile network in the Chicago suburbs, an important step in developing a national quantum internet..

The American Pharmacists Association announced that former Board of Trustee member Daniel Buffington, PharmD, MBA, will be the first pharmacist to serve as a member of the American Medical Association’s Current Procedural Terminology Editorial Panel.

Editas Medicine, Inc., a leading genome editing company, announced that it will host a conference call and webcast on Wednesday, February 26, 2020, at 5:00 p.m. ET to discuss a corporate update and results for the fourth quarter and full year of 2019..

SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced it will report financial results for the fourth quarter of 2019 after market close on Monday, March 9, 2020.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate in the upcoming SVB Leerink Global Healthcare Conference in New York, New York.

Atara Biotherapeutics, Inc., a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, announced the Company will release fourth quarter and full year 2019 financial results before the market opens on Thursday, February 27, 2020.

Incyte (Nasdaq:INCY) is proud to announce the opening call for submissions for its newly launched Incyte Ingenuity Award, an annual program created to support people living with graft-versus-host disease (GVHD), as well as their caregivers and physicians, by encouraging innovative and novel solutions for the challenges currently facing the GVHD community.

ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX) announces the progress of screening PKX-001 for cardiometabolic disorders.

LivaNova PLC commends the recent international consensus statement published in the Journal of Affective Disorders for recommendations to identify, assess and manage depression for patients unable to achieve or sustain symptom remission despite serial treatment trials.1 While the diagnosis for these patients is often “Treatment-Resistant Depression”, the authors conclude that “Difficult-to-treat Depression” has semantic and conceptual advantages.